To investigate possible central dopaminergic regulation of betaendorphin-like immunoreactivity (βE-LI) and adrenocorticotropin (ACTH) release in humans, we gave the dopamine antagonist haloperidol or placebo intravenously to twelve normal male subjects and measured βE-LI and cortisol for 120 minutes following injection. Haloperidol, but not placebo, produced significant increases in plasma βE-LI and cortisol. These findings suggest that central dopaminergic pathways such as the tuberohypophyseal system may participate in regulation of the secretion of βE and ACTH from the human pituitary.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)